To capture the economic value of innovation, innovators must demonstrate the economic and clinical value of their new product to the four key stakeholders, each with its own definition and criteria.
* FDA for market authorization * Payers for coverage and pricing * Physicians and health systems * Consumers and patients
This interactive session will highlight the challenges and opportunities posed by each of these stakeholders for firms in the life sciences (drugs, devices, diagnostics, digital therapeutics) in the United States, with examples.
Avec les Pr. James C Robinson, Université de Californie, Berkeley & Pr. Francis Megerlin, Université de Strasbourg.
Inscription gratuite obligatoire, dans la limite des places disponibles, en suivant ce lien.